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Abstract
Hemostasis is dependent on the functioning of three systems: blood vessels, 
platelets, and plasma proteins. During vessel injury, platelets adhere, secrete the 
contents of granules and aggregate. Each event in platelet activation is dependent 
upon plasma membrane proteins and a deficiency in any one of the plasma membrane 
proteins leads to excessive bleeding. Pregnancy is described as a hypercoagulable 
state during which fiequent bleeding abnormalities are observed. The mechanism of 
hypercoagulability is not yet known, hi an attempt to shed light on the 
hypercoagulable state, this study compares the plasma membrane proteins between 
pregnant and non-pregnant females.
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Quqjter 1 
Introduction
Background
Platelets are an essential mediator o f hemostasis along with the blood vessels and 
proteins of the coagulation system. Platelets are crucial in allowing the body’s 
hemostatic system to function properly through the formation o f a  platelet aggregation 
and to provide the surface for coagulation to occur. These anuclear cell fiagments 
derived from bone marrow’s megakaryocytes are not just cellular pieces designed to plug 
“leal^r’* blood vessels. These complex cell fragments contain different granules that 
release their contents upon stimulation through a signaling mechanism using receptors on 
the platelet surface. The contents o f the granules recruit more platelets and also activate 
the other systems of coagulation. The stimulation and re ^ n s e  is graded and goes from a 
normal platelet not sticking to the endothelium lining the vascular system to a “platelet 
plug” when the subendothelial cormective tissue is exposed and if  the stimulus is strong 
enough the platelets will form a ‘^ viscous metamorphasis”—an irregular mass of 
degenerated platelet material without membranes ^ arm ening, 1997). The graded 
response is dependent on the extent of damage with lAhich differing amounts of a variety 
of substances such as ADP, epinephrine, Ca^ % collagen, thrombin, and thromboxane are 
released to stimulate the platelets. This platelet system is held in check to keep the 
vascular system intact but not to have the platelets overactivate occluding blood vessels 
yielding the surrounding tissues hypoxic.
During pregnancy the female body changes to accommodate the developing fetus 
within a placenta This includes alterations in die hemostatic mechanism and its
parameters. Coagulatîoa fiictors that increase during pregnancy include &ctorsVn,VIII, 
X, x n , and vWF. There also seems to be a  suppression o f fibrinolysis, an increase of 
soluble fibrin, and an increase in fibrin degradation products ^ D Ps) (O’brien, 1986).
The platelet count during p regnan t is controversial with some studies demonstrating no 
change and others indicating a slight decrease in platelet number ^ erry, 1992). the 
hemostatic changes described above, pregnancy has been referred to as a state hyper- 
coagulatioiL
Problem Statement 
Pre-eclampsia is a complication related to pregnancy characterized by 
hypertension, proteinuria, and edema. Pre-eclampsia affects between 1-5% of 
pregnancies. When the triad of symptoms is accompanied by convulsions the term 
eclampsia is used. This occurs in 0.05% of the pre-eclamptic gravids and the damage to 
mother and fetus is obvious. While the diagnosis is quite clear the cause and treatment 
are no t Though thrombocytopenia is clinically seen in only about 15% of pre-eclamptic 
patients, the platelet has been hypothesized as the source of the problem. Many studies 
have shown that the platelet is hyperactivated during pre-eclampsia (ie. Norris et al. 1993 
and Kilby et al. 1993). As to date, there is no known cardiovascular or hemostatic 
predictor, including platelet factors or markers, that are able to predict Wiether pre­
eclampsia will occur in a patient The platelet is hypothesized to be the cause of pre­
eclampsia primarily in the fact that aspirin treatment lessens the damaging effects of pre­
eclampsia. Aspirin inhibits the cyclooxygenase enzyme on the platelet membrane vdiich
is responsible for converting certain membrane ^ xos^m% ids mto tfnomboxane, a  potent 
platelet aggregator and vasoconstrictor.
How the platelet becomes hyperactivated during pre-eclampsia is unknown. It is 
not even known if  and how the platelet changes during normal pregnancies. Before the 
platelet changes are compared betwem normal pregnant and pre-eclamptic patients it 
must first be established Wiether the platelet changes normally occur during pregnancy 
along with the other hemostatic parameters.
Purpose
The purpose of this study is to establish Wiat changes occur to the platelet during 
normal pregnancy. Platelets will be examined fiom two populations: noiq*regnant 
females and normal pregnant females. Normal pregnancy in this context refers to 
pregnancy uncomplicated by hypertension, thrombocytopenia, or pre-eclampsia. A 
compete blood count will be run to evaluate platelet count, platelet distribution width 
(PDW) and any CBC abnormali^ revealed. Flow cytometry will then be used to study 
the changes to different receptors on the platelet membrane including the receptors for 
platelet adhesion, platelet aggregation, and different receptors indicating activation.
This study will discern whether pre-eclampsia is most likely due to an 
overcompensation o f the platelet to the added pressures on the body during pregnancy or 
whether it is a disease state unlike any changes that occur to the platelet
Research Hypothesis
During pregnancy, the female’s body^  changes to compensate for the growing 
fetus. Changes in the platelet membrane receptors are also included in the overall 
changes in the female’s body during pregnan^.
Hypothesis
1) During normal pregnancy, there are increases in platelet proteins iNiiich are 
essential for platelet function (GP Ib, GP DC, GP IV, GP lib , and GP m a).
2) During pregnancy there is an increase in circulating activated platelets.
Chapter 2 
Literature Review
Introduction
The three components o f hemostasis, the arrest o f bleeding, are the blood vessels, 
platelets, and the plasma proteins. Blood vessels play a role by vasoconstricting during 
vascular injury. Platelets provide primary hemostasis, udiich is described as the 
aggregation of platelets forming a platelet plug at the site o f injury. The third component, 
plasma proteins, provides secondary hemostasis by forming a  strong fibrin clot, 
reinforcing the platelet plug.
Vascular system
The vascular system helps to prevent bleeding by two mechanisms. First, it 
contracts the damaged vessels, vasoconstriction, and secondly it relaxes the surrounding 
vessels which diverts blood flow around the damaged vasculature. The vascular system 
not only reroutes blood flow around damaged vasculature it initiates primary and 
secondary hemostasis. Only when the integri^ o f the endothelial cells lining the blood 
vessels is comprimised do platelets begin aggregation and thrombin begins converting 
fibrinogen into the fibrin clot. Thus, the vascular system prevents indiscriminate 
activation of the other hemostatic mechanisms.
Platelet 
Origin/lifecvcle
The platelet or thrombocyte is a cell fiagment of the largest hematopoietic cell, 
the megakaryocyte. An understanding of the platelet- megakaryocyte system is crucial in 
understanding the clinical significance o f pre-eclampsia in which thrombocytopenia and 
other changes in the platelet are observed.
All hematopoietic cells begin, as apleuripotent stem cell in die bone manow. 
These pleuripotent stem cells have the ciqncity^ for both continuous replication and 
differentiation (Hiarmening, 1997). The differentiaition occurs via different actions o f 
cytokines, i^ c h  are soluble mediators o f cell communication. Two groups o f cytokines 
involved in megakaryopoiesis are colony stimulating Actors (CSFs) and interleukins 
(ILs). Through the actions o f the different CSFs and ILs these pleuripotent stem cells 
differentiate into a CFU-GEMM, colony forming unit- granulocyte erythroid, 
monocyte/macrophage, megakaryocyte. The CFU-GEMM is a semicommitted stem cell 
)Ahich is the progenitor cell o f the myeloid Amily o f blood cells ^arm ening, 1997). 
Under the directions o f certain specific cytokines the CFU-GEMM differentiates into a 
megakaryoblast.
The megakaryoblast is a premature form o f the megakaryocyte. A staging system 
has been established to follow the maturation of the megakaryoblast to the 
megakaryocyte using four defined criteria. These four criteria, nuclear to cytoplasmic 
ratio, nuclear shape, basophilia, and cytoplasmic granularity, conveniently divide foe 
maturation process of the megakaryo^te into four stages (Rifidn, 1998). It is important 
to note that during the maturation process the megakaryo^tic cells are able to undergo 
endomitosis. Endomitosis refers to the ability of a cell to undergo mitotic divisions 
without cytoplasmic divisions generating very large multinucleated or polyploid cell 
(Rifidn, 1998). The megakaryocytic cells can therefore have 1 ,2 ,4 ,8 ,16 , or even 32 
nuclei. Each nucleus will contain the diploid set o f chromosomes and therefore the 
average megakaryocyte, vAich contains 8 lobes, will have 16 single sets of 
chromosomes, referred to as 16N.
The four stages of the m egakaiyo^te maturation include the megakaryoblast 
(stage I), the promegakaryot^te (stage IQ, the granular megakaryocyte (stage UT) and 
finally the megakaryocyte. The cell size increases during this maturation process fiom 
about 15-50 um in diameter fi>r the megakaryoblast all the way iq> to megakaryocyte, 
vdiich can be 100 um in diameter. During the maturation, endomitosis is also occurring 
and the nuclear/ cytoplasm ratio is changing  fiom about 4/1 to between 1/1- 1/12 in the 
megakaryocyte. The cytoplasm becomes more granular as maturation is occurring, 
mostly due to an increase in the numbers o f mitochondria and polyribosomes, both of 
vdiich are important structural constants needed to fuel the cell and m ake die proteins that 
will be shedded into platelets. During this maturation a  network known as the 
demarcating membrane system (DMS) is forming via invaginations o f the plasma 
membrane (Rifidn, 1998). The DMS becomes the future plasma membrane system of the 
megakaryocyte offspring—the platelet. By the time the megakaryocyte matures the DMS 
has become very extensive and through here platelets will bud off.
The platelets shed fiom the megakaryocyte usually near a venous sinus vdiich 
facilitates the shedding (Rifidn, 1998). The platelets do not leave the marrow through a 
fenestrae but rather the proplatelets squeeze through the endothelial cell bodies. Each 
megakaryocyte can shed between 1,000 and 5,000 platelets. Once the megakaryocyte is 
exhausted it undergoes pyknosis and is phagocytized by neighboring macrophages. The 
platelets that are shed are between 1 and 4 um in diameter and 0.5 and 1.0 um in 
thickness. They may be round, oval, or rod sh^ied and appear as dense blue to purple 
particles with granules that stain with graded intensif during Romanowsky stain 
preparation (Rifidn, 1998). Once in the peripheral circulation, platelets are thought to
circulate between 8 and 12 days. I f  one assumes a  nonnal platelet count o f150,000 and 
450,000 /  ul a steady state turnover would require 1.2-1.5 *10 11 platelets shed/ day 
(Rifkin, 1998). Of the total population o f platelets in the body one-third are found 
sequestered in the spleen and these become available for use upon need.
Structure o f the platelet 
A description o f the platelet anatomy is important to discuss in order to more folly 
understand what changes occur in the platelet during pregnancy and preeclampsia. 
“Structure dictates fonction,” is a quote often told to beginning physiology students and 
in this case a discussion o f the structure will clarify later sections on function o f platelets 
and the mechanism by which this occurs. There are three areas of viiich the platelet 
anatomy can be divided; the plasma membrane, the cytoskeleton (sol gel zone), and the 
organelles. Each will be discussed separately.
Plasma membrane
The platelet’s plasma membrane is ^proximately 7.5 nm thick and has the ^ i c a l  
phospholipid trilaminar structure. Overlying the plasma membrane is a surface coat of 
glycocalyx that is betweenlO and 50 nm thick. There are a number of glycoproteins 
present in this layer including: la, Ib, Ic, Ha, Hb, m , IV, V, and DC (Rifkin 1998). These 
glycoproteins are receptors essential for normal platelet function: adhesion, aggregation, 
and secretion, which will be discussed later. The glycocalyx also provides a surface to 
which some factors of the coagulation system may adhere. The underlying plasma 
membrane is also very important for platelet fonction. The ionic pumps within the 
membrane maintain the ionic gradient The phospholipid constituents provide a source of 
fatfy acids used by certain enzymes to generate prostaglandins, Wiich are potent
vasoactive agents (Moncada, 1979). The platelet plasma membrane also contains some 
of the tiictors o f the coagulation system and is also a place \^iere certain coagulation 
enzyme complexes are assembled. The platelet has a  series o f channels throughout it 
called the open cannalicular system (OCS) lAinch are «tensions o f the plasma 
membrane. Though the platelet is usually referred to as “discoid a  more useful mental 
image o f platelets may be of small sponges.” (Ault, 1993) The OCS increase platelet 
surface absorption allowing increased numbers of plasma procoagulants to be collected 
increasing fibrin fermation and platelet stored products can also be released more rigidly 
through here (Harmening, 1997).
Sol Gel Zone
The cytoskeleton or sol gel zone is the part o f the platelet that is responsible for 
the structural arrangement of the platelet. Microtubules and microfilaments are the two 
main components o f the cytoskeletoiL The microtubules ferm a circumferential band 
around the periphery o f the cytoplasm maintaining the platelets discoid s h r^  (Rifidn,
1998). During platelet stimulation the microtubules contract toward the center of the 
platelet “bringing the organelles towards the interior and their reorganization tniiich 
facilitates the secretory process” Qlarmening, 1997). The microtububules will also later 
appear in the pseudopods. During stimulation the microtubules appear to prevent 
secretion in response to a minimal stimulus. The microfilaments are responsible for the 
pseudopod formation in the stimulated platelet Two proteins associated with the 
microfilaments, actin and myosin, are contractile proteins by nature and fecilitate the 
quick response of the activated platelet Though it is not clear how this occurs certain 
fects are known. Platelet activation via an agonist increases intracellular Ca? ,^ vhich
activates ceitainmiat>fîlament binding proteins. One example is gel solin^diiclLiKiien 
activated by the increased Ca^, severs actin filaments which is thought to be important in 
microfilament reorganization (Williams, 1999).
The cytoskeleton is also important in that it is tied in with other platelet structures. 
The GPnb/nia fibrinogen receptor is an example. It is known that a portion o f the 
receptor is fimctionally and structurally linked to the cytoskeleton. &q*eriments have 
shown that if  the microfilaments cannot polymerize partud inhibition is seen with the 
induced activation via the GPUb/UIa receptor (\K^Uiams, 1999). hi the unstimulated 
platelet, though, the microfilaments are scattered throughout the platelet ready to contract 
with the proper stimulus.
Organelles
The organelles constitute the major portion of the platelet cytoplasm. These 
structures include: dense bodies, a  granules, and mitochondria. Other structures are less 
prevalent but are still required for proper platelet function and include lysosomes, 
perioxisomes, and glycogen granules (Harmening, 1997).
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The a-granules are the most numerous granule in the cytoplasm numbering about 
20-200/ platelet. The a-granules contain mainly coagulation Actors and proteins 
involved with platelet aggregation. Table I shows many o f the different contents o f the 
a-granule. Some of these factors will be discussed in the tq)coming sections because o f 
their importance in magnifying or changing the platelet activify or the coagulation/ 
vascular system’s activify. Two examples o f the importance o f secretion of the a-granule 
is in the Actors, platelet Actor 4 (PF4) and p-thromboglobulin. Both Aese substances 
bind heparin and neutralize it ^ ifk in , 1998). Heparin is Ae primary inhibitor of 
thrombin, viiich stabilizes a clot and Aerefore Ae roles o f Aese Actors is obvious.
The dense granules are less numerous Aan Ae a-granules (2-10/ platelet) and do 
not contain as many different substances. Table 1 also lists Ae contents of Ae dense 
bodies. Probably Ae most important substance released from Ae dense bodies is ADP. 
This is a platelet aggregator but it’s Auctioning time is short lived. After it’s rapid 
breakdown it is converted into adenosine which indirectly decreases aggregation (Rifkin,
1998). The Ca^  ^and Mg^^ released are important in activating different mechanisms of 
Ae platelet. A more detailed Ascussion of some of Aese factors and substances is 
forAcoming.
The review by Rifkin (1998) states that **Ae significance of Aeir (Ae lysosome) 
release is unclear, however during platelet secretion lysosomal contents are released more 
slowly and mcompletely than oAer granules.” The lysosomes may Agest substances that 
Ae platelet endocytoses but Ae *‘pAtelets have limited abilify to phagocytize any 
constituent” (Rifidn, 1998). An article by Sternberg R ifidn, 1998) adds that Ae 
lysosomes require stronger agomsts for release than a-granAes, and this woAd suggest
II
that lysosomes have a  greater role in lysis of thrombin than in mediating a hemostatic
response.
A description o f platelet origin and structure has been put forth. The role of 
platelets and the plasma coagulation system will be discussed next along with how the 
platelet is involved in Üiis system. An overview oftfae coagulation system with die 
platelets role will be important to future sections vhich will be going into very detailed 
descriptions o f specific receptors and Actors involved in the platelets role in hemostasis. 
This study is examining whether changes occur with the platelet receptors during 
pregnancy and therefore such a description is necessary.
Primary HemoRta«ris
After damage to a blood vessel subendothelial connective tissue is exposed. The 
platelet will reversibly adhere to the subendothelium via a plasma protein, von 
Willebrand Factor (vWF), and a receptor on the platelet called glycoprotein Ib (GPIb). 
The platelet can also n^idly adhere and be activated by collagen direcdy. This initial 
adhesion acts to plug the site of bleeding. If the damage is more severe platelet 
aggregation and the release reaction will occur. It is difficult to separate these two events 
since they are closely tied together. These two processes occur if  a stronger stimulus is 
present leading to granule release, hi vivo, a platelet usually experiences the action of 
several agonists (ie. collagen, ADP, TXA2 , adrenalin, and thrombin) and it is the synergy 
that determines the extent of platelet activation. The release reaction occurs with the 
dense granules first dumping their contents into the extracellular plasma followed by the 
a-granules. Within the granules are many different substances, two of i ^ c h  are ADP 
and Ca^\ These two serve to amplify the process, making this a positive feedback loop.
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The platelets go through an irreversible s h ^  change with the pseudopod fomiation. A 
third Actor released, fibrinogen, binds to it’s receptor on the platelet surface (GPIIb/nia) 
with C a^ aiding in the ligand formatiotL
Secondary hemostasis 
The goal of the coagulation system is the formation of fibrin. Through a cascade 
of biochemical events thrombin is activated and then converts fibrinogen into fibrin, 
which stabilizes the initial platelet plug that has formed at the site of vascular injury.
Most factors involved with the coagulation system normally circulate in an 
inactive state. Once one is activated the others follow like a waterfall or cascade. There 
are three divisions of this system an intrinsic, an extrinsic, and a common pathway where 
the intrinsic and extrinsic m eet Figure 1 illustrates these systems.
Contact Collagen
HMWKXII
HMWK PK
T issue Thromboplastin
Ca**
PF3
VIII
Prothrombin
Xllla
Stable 
Fibrin 
^  Polymer
Stable 
Fibrin 
7  MonomerFibrinogen
FIGURE 1
The activation of the intrinsic pathway occurs t^ e n  blood is eiqiosed to collagen 
or the endothelial basement membrane. Factor XII, normally present in plasma.
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undergoes a confoimaticnal change ixAen bound to these substances and becomes 
activated. Factor XHa hydrolyzes ptekallekrein and Factor XT, if  HMWK, aco&ctor, is 
also present Prekallektein is cleaved into kailekrein. Kallekrein is an en^m e, vdiicb 
can form bradykimn, a  potent substance in the inflammatory process and secondarily it 
feeds back and potentiates Factor XUa. The other factor, XIa, will activate Factor DC in 
the presence o f the n«ct step in the cascade. Factor DCa will participate in the 
formation of the Xase complmc on the activated platelet’ s membrane. The other 
participants are Factor Vm, Ca^% and PF3. PF3 is not a specific factor but rather the 
state o f the activated platelet sutfiue. ‘The activated platelet surfiice accelerates these 
complexes (Xase and prothrombinase) several thousand fold by increasing proximi^ and 
concentration o f reactants and provides the appropriate phospolipid moieties needed for 
both reactions... this was formally referred to as PF3 activi^ (Rifkin, 1998).
The Xase complex is the begimiing of the common pathway and will activate 
Factor X. Factor X can be activated by the extrinsic pathway, which begins with Factor 
Vn. When a vessel wall is damaged, tissue factor (also referred to as Factor m  or 
thromboplastin) is released. If  any Ca^ is present Factor VII will be activated to Factor 
Vila via a conformational change rather than a peptide bond cleavage.
Factor Xa will join with Ca^  ^and Factor V to form the prothrombinase complex 
on the activated platelet membrane ^F3). Prothrombin is now converted to thrombin. 
Thrombin will convert the fibrinogen into fibrin monomers. Thrombin, though, has other 
functions to aid in the clot formation. It feeds back to increase the amount of Factors V 
and v m  thereby amplifying the intrinsic cascade. Thrombin also activates Factor Xm  
which crosslinks the fibrin monomers into fibrin polymers. The crosslinked clot is now
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stronger and less likely to n^idly be dissolved by the fibrinolytic system. Thrombin has 
the function to activate parts of the fibrinolytic system aiding in the lysis of the fibrin
clot
Mechanism o f  platelet activation 
C a^ plays a  critical role in platelet activation. The mechanism by which this 
occurs is shown in figure 2. The extracellular agonist will activate a  G protein and this G 
protein activates pho^holipase C (PLC). PLC cleaves phosphatidyl inositol 4 ,5- 
bisphosphate, PIP2, into two signaling molecules- one is membrane bound, 
diacylglycerol, DG, and the one that is cytosolic is inositol 1,4,5- trisphosphate, IP3.
p —P latelet membrane
I '------ 1
^ ^ ^ P h osp hoid nase C
Î
Î
^  Both serve to
increase Intracellular Ca++
Phosphollpase C
Receptor with 6  protein 
Extracellular agonist
FIGURE 2
Results of 
Increased intracellular Ca++ 
Fibrinogen Receptor Exposure 
S hap e Change 
Granule Secretion  
Arachidonate Liberation 
A dd Hydrolase Secretion
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Both o f these serve to elevate ^ tosolic IP3 (via C a^ sensitive channels within the
platelet) and DG (via activating other Idnases, protem kinase C ^ K Q ). Platelet response 
is executed by the concentration o f C a^ in the cytosol with slupe change requiring the 
smallest amount and aggregation requiring a higher amount (Holmsen, 1994). Figure 2 
also indicates that the C a^ will lead to granule release providing proof that Ae positive 
feedback loop does occur.
Thromboxane synthesis
In addition to increases in C a^ during platelet activation, thromboxane is 
synthesized and released. Thromboxane (TXA2) is a potent platelet aggregator and 
vessel wall constrictor. The pathway by viiich TXA% is made and how it is regulated is 
important in a discussion o f platelet activation. Platelet agonists such as collagen, 
thrombin, and ADP activate phospholipase A2. \ ^ c h  is an enzyme that hydrolyzes 
arachidonate in the membrane to 6 ee it 6 0 m the membrane. Free arachidonate is 
oxygenated by two different mechanisms, the cyclooxygenase and the lipoxygenase 
pathways, though the roles o f the byproducts of the lipoxygenase pathways are unclear 
(Holmsen, 1994).
The cyclooxygenase pathway takes arachidonate and converts it into different 
products, one being TXA2 . TXA2  induces platelet aggregation via decreasing the levels 
of cAMP in the platelet Aspirin, v*ich is a cyclooxygenase inhibitor, can be used to 
prevent thrombotic phenomenon and therefore the importance of TXA2  in platelet 
aggregation can be seen ^ oncada, 1979). TXA2  activiy is short lived: it is an unstable 
molecule with a half life of only 30 seconds and the byproducts do not affect platelet 
aggregation ^ oncada, 1979). The potency of 7 XA2  action needs to be regulated.
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otherwise major tliiombotîc events will occur. A second product o f the qrcloo:qrgenase 
padiway is prostacyclin (PGI2), %*indihas anti platelet aggregatory properties along with 
vasodilatory properties o f vessel walls. Figure 3 shows the balance between the two 
prostaglandins. Prostaqrclin is not made in the platelet but rather within the endothelial 
cells lining the blood vessels. Prosta^clin serves to activate adenylate cyclase increasing 
cAMP levels so under normal conditions TXA2  and PGI2  counteract each other’s actions 
to maintain homeostasis with respect to platelet function (Walsch, 1998). Duiinga 
pregnancy complicated by pre-eclampsia and/ or pregnancy induced hypertension (PIH) 
it is hypothesized that platelets increase their production o f TXA2  and therefore the 
increased hypertension and platelet activation would be seen. This study will be looking 
at whether increased platelet activation is occurring during pregnancy and therefore the 
results of this are obvious.
I Wall
Thremboxan*
FIGURE 3
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Glycoprotein Ib is the platelet receptor re^mnsible for initial platelet adhesion via 
a plasma protein called vWF. The receptor is a  tetramer o f four different units each 
having a function in the cell signaling. While vWF is the primary ligand for this receptor 
it is not the only one. Thrombin also uses one type o f GPIb to initiate its strong 
activation properties. The signaling mechanism once GPIb is activated is partially 
understood and it is known that vWF and thrombin use different mechanisms. vWF 
changes its conformation according to the shear stress within the blood vessel and these 
different conformations have different platelet activation potentials. Looking at these 
points in depth will give a greater understanding i^Aat GPIb does and how it interacts 
with the platelet and hemostasis. This discussion will clarify vdiy changes in its number 
or density could be responsible for the hypercoagulable state seen in pre-eclampsia.
The platelet glycoprotein Ib is formed from four homologous polypeptide 
subunits, GPIba, GPIbp, GPDC, and GPV, and each of these is encoded by a unique gene 
(Dong, 1997). There are about 25,000 GPIb complexes/ platelet and this complex can be 
seen in figure 4 below. Though the vast majorify of receptors exist on the platelet surface
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certain studies have shown GPIb receptor localization to vacuolar structures, but the 
researchers are not able to differentiate \idiether these are true vacuoles or parts o f the 
OCS (Drake, 1986). GPHxr is by ferthe largest subunit, with over half o f the total mass 
in it and it contains the longest cytoplasmic domain, totaling about 100 amino acids. This 
region was shown to mediate associations with the cortical cytoskeleton o f the platelet by 
directly binding actin binding proteins (ABP) and diis association may modulate ligand 
binding (Dong, 1997). This subunit is also responsible for the vWF and thrombin 
binding. The Dong article also demonstrated through truncated receptors that GPIba 
helps anchor the receptor complex in place to provide the optimal conformation to bind 
vWF.
The GPIbp subunit is said to serve as a link between GPIba and GPIX even 
though there is a disulfide link between GPIba and GPIbp but only a noncovalent 
association between the other subunits. GPV’s role in this complex is mostly unknown 
but studies have indicated that GPV is required for efGcient surface expression of GPIba 
and GPDC (Parisse, 1999).
The mechanism by which GPIb signals the platelet to activate is also complex. In 
general, activation via vWF causes the breakdown of PIP2  in the platelet membrane 
leading to an increase in cytosolic Ca^. Figure 4 also showed a 14-3-3 protein attached 
to GPIba. This is thought to be the human isoform ofPLAz v»iiich is the en^m e known 
to produce TXA2  (Parisse, 1999). The third signaling mechanism associated with this 
receptor is the ABP. This protein is cleaved by a protein called calpain Wiich then 
allows it to depolarize the platelet cytoskeleton so actin filament reorganization can occur 
which is part o f platelet activation discussed previously. An article by Yuan et al. (1997)
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showed that vWF activatioilof GPIb can induce ^ toskeletaltxaiislocation in aggregating 
and spreading platelets. This can occur indepauknt o f GPHb/ma, which is the receptor 
known to play a central role in cytoskeletal signaling.
vWF is the primary Actor that activates GPIb. Itmduces adhesion, aggregation, 
and spreading of activated platelets. vWF ckculates in plasma at TugAni and is also 
present in a-granules and weibel palade bodies of endothelial cells (Siedlecki, 1996). 
Upon blood vessel injury vWF is eiqmsed and mediates platelet adhesion. vWF changes 
its conformation depending on the shear force in the surrounding circulation so it is more 
active in microcirculation and stenosed arteries. It was not until 1997 when Siedlecki et 
al. proved the hypothesis and demonstrated that inactive vWF was a globular protein and 
as shear force was increased protein unfolding occurred and vWF took an extended 
conformation. They also showed vWF binds to any hydrophobic surface and being such 
a large molecule (260 kDa) the greater the shear the more hydrophobic contacts between 
it and the underlying connective tissue, artificial cardiac devices, or components of 
arthesclerotic plaques. A study by Chow et aL (1992) demonstrated that platelets in a 
high shear environment will have an increased cytosolic Ca^ .^ The important point they 
made was that this was entirely fiom a transmembrane infiux o f Ca^\ The kinetics o f 
this response is slower than say Ca^  ^release via thrombin or ADP wdiich releases Ca^  ^
from internal stores but this transmembrane infiux of Ca^  ^preceded ADP release. They 
showed that vWF binding to GPIb is absolutely essential for shear stress induced Ca^  ^
influx which lead to aggregatory response vddle vWF binding to GPIIb/nia potentiates 
the shear response but is insufQcient to do this without GPIb (the mechanism by vddch 
this is mediated is still unknown) (Chow, 1992).
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While vWF is Ae primary ligand for GPIb, thrombin is another. Thrombin is 
known to have greater than one receptor on platelets and one is known to be on the GPIb 
receptor. The GPIb thrombin receptor is known to be a high a£Bni^ receptor for 
thrombin (-50/ platelet) and is associated with other membrane proteins (molecular 
weight ~9001dDa as opposed to normal GPIb —190kDa). It was demonstrated that foe 
high affinity thrombin receptor mediates its response through phospholipase A% as 
opposed to a  moderate affinity  ^thrombin receptor acting through a  G protein (Greco,
1996). There are several lines o f proof for this: 1) foe moderate affinity receptor has been 
shown to activate a G protein, 2 ) the 14-3-3 signal transducing protein (PLAz isoform) 
has been shown to be associated with GPIb and 3) PLAz itself has been shown to be 
activated by foe binding of vWF to GPIb. Though foe high afSnity thrombin receptors 
are described here, vWF is foe primary ligand in platelet adhesion via GPIb. vWF can 
bind to GPUb/nia in certain situations. GPIIb/IIIa is an integrin receptor and foe most 
numerous receptor on foe platelet membrane. vWF has an amino acid sequence ^ G D ) 
which can sometimes bind to GPIIb/IIIa and aid in adhesion. GPIIb/IIIa will be 
discussed in detail in foe next section.
GPnb/nia
GPUb/nia (also referred to as cdlbp3) is foe primary receptor responsible for 
aggregation, primarily binding to fibrinogen. It is a member o f foe integrin fomily, which 
is a class of receptors binding cells to foe extracellular matrix. After reviewing its 
structure its unique signaling mechanism will be examined. The receptor’s function and 
ligands will be thoroughly discussed in foe signaling mechanism outline.
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GPnb/nia is composed of noncovalently linked a  and p subunits. The a  and P 
monomers form a one to one ratio of Ca^  ^and heterodimer complex and it is the 
extracellular Ca^  ^that affects the receptor’s structure and function. Ca^  ^helps maintain 
the physical integri^ that is required for activation induced expression of the fibrinogen 
(Fb) receptors and Fb binding (Sims, 1991). The bulk o f the integrin is octracellular with 
the short intracellular portions being responsible for regulating the conformation o f the 
receptor, (see figure 5) The structure of GPIIb/IIIa, explained basically is very complex 
and “its structure and binding properties indicated the presence of domains involved in a 
number o f major functions including: subunit association, conformational changes 
exposing the ligand binding pocket, extracellular ligand recognition and binding, ligand 
induced expression of neoepitopes, membrane associated receptor clustering, and 
cytoskeletal interactions” (Calvette, 1995). The GPIIb/HIa receptor does not bind to 
fibrinogen unless the platelet is stimulated through a process referred to as inside-out 
induction of fibrinogen binding.
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Li an inig»imnlat«;«i platelet GPnb/nia is maintained in an inactive confonnation 
and serves only as a  low affînity  ^adhesion receptor for surfoce coated fibrinogen 
(Calvette, 1995). Through a system o f intracellular signals, udtich occur after platelet 
stimulation, the extracellular globular portion undergoes a change in quaternary structure 
opening up the Fb binding site. An amino acid sequence o f ROD, Wxich is found on 
fibrinogen, vWF, vitronectin, thrombospondin, and other binding proteins, binds onto this 
newly exposed site. The Calvette review states that if  the RGD sequence extends 
between 11-32 angstroms fiom polyacrylnitrile beads it can be bound by GPUb/nia on 
the unactivated platelet and this sort of “RGD «[tension" is only available uiien the 
binding proteins are insoluble which prevents premature aggregation. The mechanism by 
which the binding site is «cposed is unknown but an article by Sims et al. puts forth some 
ideas. Other studies have shown that through TXA2  or thrombin Fb receptors can be 
induced by G proteins and their cascade involving PKC. Other platelet activators, such 
as ADP and epinqihrine, expose Fb recqitors without PKC activation and '*the metabolic 
pathways involved in this circumstance as well as the event ultimately responsible for Fb 
receptor exposure remain to be characterized” (Sims, 1991). One signaling mechanism 
that is hypothesized by Savage involves vWF and GPIb. Savage states that “vWF 
interaction with GPIb is coupled to a signal transduction mechanism leading to PKC 
activation. This in turn may activate GPUb/UIa allowing it to siq>port irreversible platelet 
adhesion to immobilized vWF. . ." A study by Du et al. (1993) discerned that long 
distance conformational changes occurred with this inside out signaling. Thqr found that 
the “intracellular binding site was 16nm fix>m the Fb binding site and near the membrane
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spanning domain... such (long distance confonnational) changes aie likely to be involved 
in bi-diiectionai signaling by this receptor Q)u, 1993).
D uctal, xefened to bi-dhectional signaling which means that not only is there 
inside out signaling but also outside in signaling. The Du article makes reference feat 
this pair of receptors also acts in concert so each increases binding afBni^ of fee other. 
The outside in binding refers to fee Fb binding to fee octracellular domain o f fee 
GPnb/nia receptor. This binding causes confermational changes on both Fb and 
GPIIb/nia i^ c h  expresses neoepitopes called LIBS (ligand induced binding sites). The 
exposure of the LIBS correlates wife cytoskeletal independent clustering o f occupied 
GPnb/nia complexes in fee plane of fee membrane followed by platelet aggregation and 
attachment of GPIIb/IIIa patches to fee cytoskeletal network (Calvetti, 1995). He goes 
on to state that 'though fee physiological significance of LIBS erqjression remains to be 
established it is tempting to speculate that fee exposure o f fee neoepitopes in fee C- 
terminus of Hla extracellular domain could be related to mq)ression o f interacting 
surfaces for other platelet and/or plasma components” (Calvetti, 1995).
Through fee extracellular- intracellular binding GPIIb/nia also becomes attached 
to the platelet cytoskeleton. This attachment is necessary for clot retraction to occur and 
appears to trigger a major cytoskeletal reorganization. Through activated GTP binding 
proteins, PKCs, sic tyrosine kinases, and other signaling mechanisms fee <tytoskeleton is 
reorganized in different steps "leading to fee assembly of a  multimeric signal 
transduction complex, vfeich may explain the causal relationship between GpIIb/nia 
occupancy and a number o f intracellular events elicited by ligand binding such as
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increase in NaVH^ exchange, intracellular pH, phosphatidyl inositol metabolism, calpain 
activation, and thrombin induced phosphoQnosme dephosphorylation” (Calvetti, 1995).
One final function o f the GPIIb/IIIa receptor has to do with an antithrombotic 
mechanism. Wencel-Drake et al. (1996) were able to show that afier platelets had been 
stimulated, a certain time passed and then the platelets became nonadhesive even though 
Fb binds irreversibly to GPIIb/IIIa. This occurred because the receptor uinch bound Fb 
was being internalized via receptor mediated endocytosis. “This observation that in vivo 
older platelets mchibit a loss o f membrane as well as a-granule contents supports the 
concept of recurrent cycles o f circulating platelet activation and recovery” (Wencel- 
Drake, 1996). The study that showed that GPIb was being internalized also showed that 
“a major difiuse intracellular pool of GPIIb/IIIa was seen and that the antigen to the 
receptor was localized to a granule membrane” (Wencel- Drake, 1996).
Though GPIb and GPIIb/IIIa are the primary receptors involved with platelet 
activity, others do play a  role in platelet function. One is GPIV, a collagen receptor. 
During exocytosis o f the a-granule the previously internal granular membrane is everted 
on the extracellular surface revealing receptors that had been confined internally. The 
high afBnity thrombin receptors were discussed but moderate affinity receptors use a 
different signaling mechanism.
GPIV
GPIV (CD36) is an 8 8  kDa platelet membrane protein and normal platelets have 
about 30,000 GPIV/ platelet The function of this receptor has largely been discerned 
form the NaK phenotype, people with this phenotype completely lack this receptor 
(Parisse, 1999). GPIV is the receptor for collagen V and NaK deficient individuals have
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no clinical bleeding disorders and no problems binding to any other type o f collagen (I, 
m , IV) except for collagen V (Saelman, 1994). Type V collagen differs fiom the other 
collagens in many respects especially in that though it is present in all extra cellular 
matrices its concentration is fiur below those of other collagens, primarily 1 and in  
(Kehrel, 1993). The Kehrel article did point out that though collagen V was in low 
concentration in normal patients, it was present in abnormally high levels in patients with 
inflamed fibrotic tissue.
The Kehrel study showed that GPIV deficient platelets aggregated normally to the 
major platelet agonists. T h ^  hypothesized that GPIV is a direct receptor for collagen V 
and is important in mediating a signal arising fiom collagen V. The Saelman study goes 
a step farther and states that, “collagen type V as fibrillary collagen may be present in 
mixed fibrils together with collagens 1  and IH and it is conceivable that interactions with 
GPFV may enhance the interaction of platelets with such fibrils” (Saelman, 1994).
GMP-140
GMP-140 is an adhesion molecule known as a LECAM or selectin. This 
molecule is normally sequestered on the inner surface o f the a  granules and only appears 
on the surface of activated platelets (Ault, 1993). This makes it a perfect marker for use 
in detecting activated platelets. The previous discussion of platelet activation 
demonstrated that granular release occurred during activation, and a study by Tschoepe et 
al. (1990) reported that GMP-140 «qiression on the platelet surface of a thrombin 
activated platelet paralleled with polymerization of the cytoskeletal protein actin. An 
important distinction between the secretion o f the a-granule and lysosomal granules 
involves the completeness of the release. “Only 30-60% of the hydrolases arc secreted
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6 om the lysosomes in contrast to near 1 0 0 % fiom Üie other Ca and dense) granules’* 
(Holmsen, 1994). This means that the presence of GMP-140 on a. platelet indicates that a 
platelet has been activated vdiereas using a lysosomal marker would only yield 30-60% 
of the activated platelets.
Thrombin receptor
Thrombin is the most potent activator o f Fb binding, platelet activation, and clot 
retraction. Previously it was discussed dmtduombin acts through different types o f 
receptors- the high afBnity thrombin receptors are a subclass o f GPIb. The importance of 
thrombin to platelet activation demands a look at the moderate afBnity receptors.
The thrombin receptor is a single chain seven transmembrane spanning G protein 
coupled receptor. The mechanism for G proteins activation was discussed previously 
(see figure 2). The moderate afBnity thrombin receptor acts through a novel mechanism. 
Instead of thrombin binding to a recq>toi to activate it, it enzymatically cleaves its 
receptor afier arginine-41 in the amino terminal domain ejqwsing a new amino terminus 
that fimctions as an agonist and activates the receptor. Figure 6  diagrams this.
H3+ NH3+
IH3+Thrombin
COO-coo-
coo-
FIGURE 6
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This activation turns on the G protein cascade but dus novel mechanism does not 
allow for deactivation via the ligand releasing- the ligand is part of the receptor. A study 
by Molino et al. (1997) looked at the fate o f the activated thrombin receptors. The 
thrombin receptors are partially internalized vdnle others are shed into microparticles 
along with other integral membrane proteins. They could not account for the 6 te o f the 
40% of thrombin receptors still located on the platelet sur&ce after activation had ceased. 
It is logical, though, that platelets cannot restore the thrombin receptor function. Platelets 
only need to respond to thrombin once, afterwards the viscous metamorphosis that is left 
is incorporated into the growing hemostatic plug.
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Hemostatic chances during nonnal pregnancy 
During pregnancy, the body goes through changes to accommodate the growing 
fetus in the uterus. Part of these changes involve the coagulation system. During normal 
pregnancy, there are various effects on the coagulation system that have been compared 
to a chronic state of compensated DIC (Petry, 1992,340). Factors that increase with 
pregnancy include fibrmogen, VII, V m , vWF, X, and XII. These fectora can elevate up 
to 200% and remain elevated during pregnancy. Other fectors, such as XI and Xm, 
decrease during pregnancy. Platelet counts during uncomplicated pregnancies show 
considerable individual variation with some maintaining normal counts, some having 
slight decreases, and some having a  larger decreases nearing thrombocytopenic ranges 
(Frohlich, 1998).
Pre-eclampsia hitroduction 
Pre-eclampsia is diagnosed with the triad of symptoms that include hypertension, 
proteinuria, and peripheral edema. Some suggest that pre-eclampsia is an exaggerated 
response to the normal changes seen in pregnancy. Platelets have been described as the 
source of the problems with pre-eclampsia. Thrombocytopenia is seen in pre-eclampsia 
and its hypothesized causes will also be discussed and some theories about vdiy it occurs. 
Thromboxane (TXAz)/ prostacyclin (PGI2) imbalance has also been implicated as the 
primary cause of pre-eclampsia and this theory will be examined. Finally, there is only 
minimal literature about the predictors o f pre-eclampsia and these will be discussed. 
Other flow studies looking at platelets and pre-eclampsia have been done but their 
conclusions were different from what this study is examining.
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Hemostatic changes in nre-eclampsia 
A study by Higgins et al. (1998) looked at hemostasis in noimotensive and pre­
eclamptic pregnant females. They found that there were significantly raised fibrin 
degradation products ^D Ps) during normotensive pregnancies. PDFs are markers for 
fibrinolysis and therefore the authors suggest that fibrinolysis is enhanced during normal 
pregnancy. The authors suggest that this could be due to a reactive response to increased 
fibrin production. During pre-eclampsia, changes occur in excess of the changes already 
seen in normotensive pregnancies. The Perry review (1992) suggests “that the intrinsic 
pathway may be altered by pre-eclampsia.” This was demonstrated by an increased PTT 
seen in pre-eclampsia and he also says that the common pathway may be 
hypercoagulable. Previous studies had demonstrated higher levels of thrombin- 
antithrombin m , soluble fibrin, and FDP’s in pre-eclampsia compared to normotensive 
pregnancies. The Higgins et al. (1998) study, though, contradicted this data when they 
found that there was no significant difference in these foctors between pre-eclamptic and 
normotensive pregnancies. T h ^  account for the difference in that the previous studies 
had all used small sample groups and the pre-eclamptic patients all had severe pre- 
eclampsia. The Higgins study, on the other hand, was a proqiective observational study 
originally following 1,000 primagravid females. Also, some of the other studies used 
different laboratory methods between the two test groups while this one used only one, 
ELISA.
Platelet counts in Pre-eclampsia 
In pre-eclampsia, 15% of patients present with thrombocytopenia. There are 
several possible mechanisms, but some are more likely than others. An immune
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ttiftehanism has keen impKeated in caiimng the  Amtnhncytc^ignia via increased platelet
bindable Ig and complement. A study by O’Neill (1985) showed that a reduction in 
platelet count can be seen 6-12 hours alter mating in mice. This was also seen in mice 
fiom syngenic matings and transfer of parthenogenetically active eggs producing the 
same result He suggests that this was due to a  response in PAF, not to an immune
mechanism -
Another mechanism for pre-eclampsia associated thrombocytopenia may be due 
to the increase in Factor X fiom increased immune complexes and vascular disruption, 
but the Higgins study did not find an increase in Factor X between the two sanq>le 
groups. The most likely reason fi>r thrombo^topenia is due to an increase in platelet 
activation followed by the activated platelets being removed fiom the circulation by the 
RE system. Norris et al. (1993) showed that in vitro response to platelet aggregating 
agents in patients with severe pre-eclampsia was significantly decreased. Patients with 
moderate pre-eclampsia also showed less response with some of the aggregators, collagen 
and arachidonic acid. If the platelets are activated, granule release would have occurred 
and platelet exhaustion would ensue, yielding the results seen. One would also expect to 
see increased platelet granule contents within the plasma. A study by Gujarti et al.
(1994) showed an increase in 5-HT in plasma while others have shown increased ADP in 
plasma fiom patients with severe pre-eclampsia confirming the theory that platelets are 
activated during pre-eclampsia.
A study by Graves et al. (1992) showed that there is an increase in the platelet 
angiotensin II receptor in females with pregnancy induced hypertension ^ IH ), a  disease 
closely related to pre-eclampsia. T h ^  were able to conclude that angiotensin binding on
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this receptor caused changes in ^ tosolic C a^ indicating that this is 8  receptor 1  subtype. 
This receptor subtype has previously been shown to be coupled with changes in platelet 
cellular A small study by Kilby et al. (1993) saw that increased platelet cytosolic 
was related to essential hypertension during pregnan^. This could be related to 
pre-eclampsia and platelet activation, see figure 2 , ^ e r e  PIP2  is stimulated to break 
down and in the end, cytosolic C a^ will increase activating the platelet.
TXA^/PGT^ imbalance 
The imbalance o f two prostaglandins, thromboxane (TXA2) and prostacyclin 
(PGI2), has been implicated in being responsible for the pathogenesis o f pre-eclampsia. 
The general description of prostaglandins is found on figure 3.
During normal pregnancy the production of TXA2  is increased and this is 
consistent with the increased platelet activation of normal pregnancy. PGI2  levels also 
increase during normal pregnancy. 'However, if  altered prostaglandin metabolism is the 
major cause of vasodilation in pregnancy and there are no changes in receptor number or 
function one must postulate that the increments in TXA% will be less than PGI2, the result 
being an increase in the ratio of vasodilating to vasoconstricting prostaglandins and this 
does seem to be the case” (August 1995). The increased TXA2  leads to vasoconstriction 
and platelet aggregation if  it remains unchecked by PGI2 , which are the main symptoms 
of pre-eclampsia. It was shown that platelet sensitivity to prostacyclin is reduced by 49% 
(Briel, 1984). This would lead to increased platelet coagulability and aggregation. This 
is thought to happen in pre-eclampsia. The increase in PGI2  is not as large as in normal 
pregnancy, which leads to the imbalance in the ratio of the two prostaglandins.
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Researchers have identified the placenta as the source for the imbalance in the 
prostaglandins. A study by Fitzgerald et al. (1986) demonstrated that the increased TXAz 
in pre-eclampsia is mainly derived fiom platelets. Aspirin irreversibly si^presses the 
cyclooxygenase pathway in the platelets and reversibly inhibits TXAz production finm 
the placenta, vddch is hypothesized to be a  second source of TXAz. Their results showed 
a decrease in TXAz metabolites in the urine with a subsequent increase with stopping the 
aspirin treatment, vdiich mimicked the normal platelet turnover in the vascular y  stem.
This data does not provide any proof that the placenta is not producing some other 
foctor involved with pre-eclampsia. PGIz is primarily synthesized in the endothelial cells 
and is thought to exert its effects inaparacrine mechanism between the endothelial cells 
and the vascular smooth muscle cells. But there could be a hormonal fiictor, vdnch exerts 
the effects to the endothelial cells. Smarson et al. (1995) demonstrated that endothelial 
cell proliferation is siqxpressed by plasma but not serum fiom females with pre­
eclampsia. They hypothesized that certain cells form the placenta, syncytiotrophoblast, 
produce this toxic factor and that in pre-eclampsia this substance is shed into the maternal 
circulation in abnormal amounts. This would disnqxt the increase in PGIz synthesized by 
endothelial cells leaving the ratio fovoring TXAz and therefore hypercoagulabiliy.
Predictors of Pre-eclampsia 
Though the exact cause of pre-eclampsia remains unknown, foere are certain 
conditions, which increase the chances of developing pre-eclampsia. Women with 
progestational insulin requiring diabetes, chronic hypertension, multifetal gestation, and 
in females with pre-eclampsia in previous pregnancies are more rqit to develop pre­
eclampsia. The risk in each o f these groiq>s is further increased by elevated MAP in the
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second trimester with the risk being i^ipcoxmiately 3.3 times greater infernales with 
MAP greater than 85mm Hg. compared to below 75mm Hg (Caritis, 1998). hicrease 
MAP in the second trimester maybe an early marker for the disease but it could also 
merely be a risk fector for pre-eclampsia. Until a biochemical or physiologic madcer is 
discovered that can be used as a screening tool the at-risk population needs to be 
identified.
Other Platelet- Pre-eclamnsia Flow studies
The use of flow cytometry in identifying platelet changes in pregnancy has been 
reported. A study by Konijnenberg et al. (Feb. 1997) used markers for platelet activation 
(P-selectin, CD63, and PAC-1) and certain extracellular adhesion receptors (armexin-V 
and platelet endothelial cell adhesion molecule-1 ). They found that during platelet 
activation (via increased a  and lysosomal granule markers) there was an increase in the 
endothelial cell adhesion molecule- 1  indicating that besides granule release there were 
“other hirethro unknown mechanisms of increased surface antigen mqwsure involved 
with pre-eclampsia” (Konijnenberg, 1997). A second study by Konijnenberg (August,
1997) examined A ether platelet activation early in pregnancy could predict the 
occurance of pre-eclampsia. T h ^  found that only first trimester CD63 expression could 
be a predictor of pre-eclampsia and this was not a very strong predictor (correlation 
coefficient of 0.63).
Janes and Goodall (1994) also examined changes that occur during pregnancy. 
They found that there was an increase in the CD63 marker in normal pregnant versus non 
pregnant women but the fibrinogen binding was the same between the two groups. 
Platelet responsiveness to ADP in vitro showed a heightened degranulation response
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(CD63 expression) in nonnal pregnant con^xaredwidiAc non-pregnant contol gioiç. 
This responsiveness to was heightened with both non-proteinimc and proteinuric pre- 
eclampsia but dûs response was not accompanied by an increase in fibrinogen binding to 
GP nb/nia.
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Chuter 3 
Methods
This was a cross sectional study conqsaiing several platelet functional parameters 
between two groups o f females (non-pregnant vs. normal pregnant). This study was done 
with the cooperation of West Michigan OB/Gyn and Spectrum Health. The proposal was 
approved by Spectrum Health (Appendnc A). A ct^y of the approved informed consent 
form is present in ^ p en d ix  B.
Variables
1 . hidependent variables
The indepradent variables o f the study are nonpregnant and normal
pregnant females.
2. Dependent variables
a. platelet number
b. mean platelet volume
c. flow cytometric analysis o f
1. GP Ib, a cell surface glycoprotein necessary for adhesion 
o f platelets.
2. GP Hb, a cell surface glycoprotein expressed on the 
surface of platelets which is coupled with GPIUa.
3. GP m a, a cell surface glycoprotein ejq)ressed on the 
surface of platelets vhich is coupled with GPIIb.
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4. Activated GP Ilb/ Œa, upoa platelet activation the Ilb/IIIa 
receptor changes conformation and exposes a  "RGD” binding 
site necessary for interactions with fibrinogen.
5. GP IV, a platelet cell surface glycoprotein responsible for 
collagen V binding.
6 . GMP-140, a granular membrane protein expressed on the 
platelet surface indicative o f platelet granule secretion.
7. CD29, a general attachment receptor or integrin.
Subjects
The control group o f non-pregnant females was obtained fiom two nursing classes 
taught at Grand Valley State University’s Ebediard center. The students were recruited on 
a voluntary basis and informed consent was obtained. After informed consent was 
obtained a demographic sheet was completed by each subject (Appendix C). The groiq) of 
pregnant females was obtained fix>m the practice of Dr. Jelesma, M.D. Normal pregnancy 
is defined as noimotensive fonales who are pregnant with no reported complications and 
who are not taking anti-platelet medications. Inclusion criteria for both groups were 
females of childbearing years without hypertension. Exclusion criteria included non- 
menstrating females of childbearing years, menopausal, post-menopausal, and hypertensive 
females.
Blood Collection
Two 5 ml tubes o f EDTA blood was collected fix>m each participant through 
venipuncture using a 21 gauge or larger needle. To avoid thrombin generation, the first 5 
ml tube of blood was discarded. Vfithin two hours of collecting the blood lOOul was added
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to 1 m lof l% fonnaldehydesoluticn(at2-8 C) and mixed, preventiiig nonspecific 
activation o f the platelets. This blood was subsequently used in the flow cytometric 
analysis o f the platelets while the remaining blood was used to measure platelet
count and mean platelet volume.
Platelet size and mean platelet volume 
The blood collected in the EDTA tube was used to determine platelet count and 
mean platelet volume using a  Sysmex K-IOOO.
Preparation of platelets fyr flow analvsis 
The 100 ul of blood that was placed in I ml of 1% formaldehyde solution was 
incubated at least th ir^  minutes, to allow fixing to occur. Following the incubation, the 
blood was centrifuged at 2S00 RPM (1200*0) for 5 minutes at room temperature (20-25 
C). The supernatant was aspirated and 2 ml of PBS with 0.1% sodium azide was added to 
the pelleted blood. The pellet was resuspended by vortexing and then this was centrifuged 
at 2500 RPM for 5 minutes at room temperature. The siq)ematant was aspirated and the 
pellet resuspended in 1 ml PBS with 1% fetal calf serum and 0.1% sodium azide. The 
resuspended blood was subsequently incubated with antibodies to various platelet proteins.
Analvsis of  platelet membrane proteins 
Platelet analysis was performed by a “direcf* flow cytometric method with a variety of 
mouse monoclonal antibodies or goat polyclonal antibodies directly conjugated to one of 
two fluorescent fluorochrome labels called fluorescein isothiocynate (FITC) or 
phycoerythrin (PE). Prior to application to the flow cytometcr, the blood was fixed and 
washed according to the method described above. A 50 ul aliquot o f the resuspended blood 
was incubated with 2 0  ul of commercially available antibodies reactive to:
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*GP Ib (CD42b, FTTC, F08Q2, DAKO, Denmaric),
*GP DC (CD42a, FITC, 348083, Becton/ Dickson, San Jose, CA), 
*IntegrinBl (CD29, FTTC, 66003109, Coulter, Hialeah, FL),
•GPIV (CD36, PE, P-9312, Sigma, S t Louis, MO),
•GP Hb (CD41, FTTC, F7088, DAKO, Denmaik) and 
♦GP nb (CD41, PE, R7058, DAKO, Denmaik),
♦GP lUa (CD61, FTTC, F0803, DAKO, Denmaik),
♦GMP-140 (CD62, PE, 348107, Becton/Dickson, San Jose, CA), and 
♦activated Ilb/ IHa ^ AC-1, FTTC, 340507, Becton/ Dickson, San Jose, CA).
After incubation for 20 minutes at room temperature without stirring and isolation 
&om the light, 2 ml of PBS with 0.1% sodium azide was added. After vortexing this was 
centrifuged at 2500 RPM for 5 minutes. When the supernatant was aspirated this wash 
cycle was repeated. The pellet was then lesuspeneded in 1 ml PBS with 0.1% sodium 
azide and was then ready for flow cytometric analysis.
Flow Cytometric Analysis 
Data Acquisition
The platelets were analyzed on a Becton- Dickson FACSort flow cytometer ^ ecton- 
Dickson Xmmunocytometry Systems, San Jose, CA) equipped with Lysis II software.
The dot plot of forward angle ^ S C ) and side angle (SSC) scatter o f laser light was 
collected in log scale to establish electronic gates on the platelets. The threshold was 
established on FSC to exclude debris. Fluorescent compensation was established by 
Calbrite beads (Becton- Dickson). The first part of the flow cytometric analysis consisted 
of the data acquisition. After selecting into the Lysis program the acquisition mode was
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selected. To get optimaL results the flow cytometer was set according to the folloing 
parameters. FSC and SSC were collected on a  log scale. The FACSort detectors were set 
to: FSC ^00), SSC (322), FLl (749), and FL2 (690). The compensation was set at 1.8 % 
for FLl, 14.9% for FL2, and 0% for the other detectors. The compensation foreshold was 
set according to the FSC'H and was set at 112. The machine was selected to collect 
results flom 10,000 cells in either the medium or high collection modes. The results 
consisted o f scatter plots of the cells and the histograms of foe amount of fluorescence/ 
cell. Each sample was saved to a file for later analysis.
The second part o f foe flow cytometric analysis consisted o f foe data analysis. 
Each sample was analyzed while obtaining certain information. Figure 7 shows an 
example of an analysis. The upper left diagram shows a dot plot o f foe forward vs side 
scatters of foe 10,000 cells collected. This was collected o f a log vs log scale to obtain 
proper separation of foe platelets from foe other cells. A gate was then established 
according to where platelets land on foe scatter plot Fluourescence 1 (FLl) for FITC vs 
fluourescence 2 (FL2) for PE were «cammed on foe upper right p lo t Quadrants were set 
at about 10^  on both FLl and FL2. This value was chosen to differentiate between foe 
platelets with Ab binding vs. non-binding. This value allowed platelets with nonspecific 
binding to not influence foe results. The quandrant statisitics were printed to foe right of 
this plot and showed foe different percentages o f platelets within each quadrant The FLl 
and FL2 were examined more closely on a histogram, vfoich are foe two boxes on foe 
lower half of foe page. The histogram statistics provided foe peak and mean channels o f 
each Ab, which is directly indicative of foe peak and mean values o f foe platelet
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membrane proteins examined in the study. These arc the values used in the Results
section, cluster 4.
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Cluster 4 
Results
Number of Subjects
Blood was collected on a total o f fi>i^>foiir subjects. Included in the study were 
twen^-two nonpregnant and eighteen pregnant females. Four females were excluded 
&om the study due to the feUowing reasons: menopausal (2), spontaneous abortion 
one week after blood draw (1), and previous hystoectomy (1). The donogn^hic data 
of the two groups is located in table 2 .
Demographic Data
The average age of the nonpregnant females was 27.7 years while the pregnant 
group's average age was 29.4 years, which showed no statistically significant 
difference when a t-test was run with a cutoff at 2.750 (two-sided value at 1% 
significance). The subjective data identified that three of the pregnant females 
reported smoking during pregnancy, between two and twen^ cigarettes/ day, while 
none of the nonpregnant females smoked. Eleven (50%) of the nonpregnant subjects 
reported being on contraceptives and the only significant medication reported by the 
pregnant subjects were prenatal vitamins. Significant in the context of this paper 
refers to medications that would affect platelets or platelet activation. Both grotq*s 
had similar results to both numbers of prior pregnancies and numbers of live births (t- 
values o f-1.04 and -0.69, respectively).
Platelet Count and Mean Platelet Volume
Table 3 shows the average platelet count and mean platelet volume Q4PV) of the 
two groups. A significance level of 1% was used which gives a t-value of +/- 2.750.
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Table 2- Patient Demographic Data
Non pregnant 
Patient#
AGE
Prier Pregnandea 
#otNveliMtra 
Atterglea? 
Smotrer?
1 2 3 4 5 S 10 11 12 13 14
23 22 22 21 22 23 40 37 24 23 23
0 0 0 1 0 0 S 3 0 0 0
0 0 0 1 0 0 3 3 0 0 0
Su##
Trlphaall-2# OrtIwoepI Crtho-trtcyctene 
Cardiovaaular du/ Hypertenalon 
SlgnMIcanl reedicat Waloiy
Non pregnant
PCN
Paxit/Nordetta Survent/Albutero lavoaWfOrtttoNovum Orttiocydtn BCP-OrtIiocept 
Aattuna
Patient i 15 10 21 22 23 24 20 27 20 31 32
AGE 23 41 35 24 30 43 25 20 20 20 27
Prior Pregnandea 0 3 4 0 7 2 0 0 O O P
dotlivatdrtha 0 3 2 0 4 2 0 0 O O P
AWarglaa? PCN environmental codeine aeaaonal aeaaonal
SntoMr?
Madicatloni? BCP Trüaviln ZyrtadDepoprovera ANatta Prozac ClariWOrtlNmovum DyazideINor TylenoUoraloontr,
Cardiovaaular dx/Hypartanalon Family Hx
SignMIcant médical Natory Eczema Aathma controlled HTN
Pregnant
Patient# 34 35 30 30 30 40 41 42 43 44 40
AGE 37 20 27 33 20 22 35 30 23 20 31
Gestation (weeka) 11 12 0 11 13 13 11 10 0 0 31
Prior Pregrtandea 0 0 0 2 0 2 5 5 3 1 p
fotlhreM tha 0 0 0 2 0 1 3 4 2 0 0
AWerglea? Bactrim audalad PCN Erythromydn
Smoirer? rVa 12W10y 2AV3y
Medicationa? aynthroid SN+ Plrerganwi SNt
Canüovaautardx/Hypertenaion lut murmur
SignHIcantmedlcaZIFr atmorPAP geatOM atmorPAP MdatoneaiabnorPAP
Pregnant*
Paient# 40 50 51 55 50 57 07
AGE 31 20 34 20 31 20 27
(*ealalon(weela) 25 25 11 30 11 20 21
Prior Pregriandee 5 2 3 1 3 0 0
fonNeMrtha 3 1 3 1 3 0 0
Smotrer?
Captdoftn
Catdtovatutar dx/ttypeilaoalon 
SIgnMeanI inadlcal lilaloiy
2tVW14y
SNt
O-MCt
Contacte
SVT
OGTT148
Seasonat
Since the t-yalues were zero or very close to zero the platelet counts and MPV can be
considered equal.
Table 3. Platelet count and MPV in non pregnant and pregnant samples
Nonpregnant
(n=2 2 )
Pregnant
(n*18)
t-value *S/NS
Platelet count 
(*1 0 ^/ul)
240.3+/-45.0 235+/-45.7 0.368 NS
M. P. V.
(fl)
9.66+/-0.77 9.70+/-0.73 0 NS
* Two-sided 99% confidence interval 
Negative Controls
Negative controls were run with each series of nonpregnant and pregnant samples. 
Less that 1% of the events in the negative controls were positive for binding. The 
negative controls were mouse IgGi antibodies conjugated to FITC or PE. Figures 7 
and 8  are examples of two controls run, figure 7 for nonpregnant females and figure 8  
for pregnant females.
CD29
CD29 is an integrin fimctioning as a general attachment protein for the platelet 
to the extracellular matrix (ECM.). Figures 9 and 10 are examples of the dot plots 
and histograms of a nonpregnant (figure 9) and pregnant (figure 10) subject. The 
statistics of the histogram show a peak channel o f78.36 for the nonpregnant subjects 
and a peak channel of 123.24 for pregnant subjects. The t-test confirmed a 
statistically significant difference between the two groups (t-value of —5.34). The 
mean channels for the non pregnant and pregnant groups were not significantly 
different (values of 119.64 and 147.88, respectively and a t-value o f—2.24) Table 4
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Figure 7. Non-pregnant negative control flow cytometric results
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Figure 8. Pregnant negative control flow cytometric results
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Figure 9. Non-pregnant CD29 flow cytometric results
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Figure 10. Pregnant CD29 flow cytometric results
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suTnmari7 .es the results o f CD29. Again, a t-value o f 2.7S0 was used as a cutoff (two- 
sided t-value with a 1 % significance level fi>r this sample size).
Table 4. CD29 Binding Results in nonpregnant and pregnant samples
Nonpregnant
(n=2 2 )
Pregnant
(n=17)
t-value *S/NS
Peak channel 
CD29
78.36+/-22.9 123.24+/-30.1 -5.34 S
Mean channel 
CD29
119.64+/-46.77 147.88+/-28.57 -2.24 NS
Two-sided 99% confidence interval 
CD36
CD36 is an antibody that recognizes GPIV, a platelet surfine collagen 
receptor. It is the only identified receptor for collagen V at this time. Though 
collagen V is less prevalent than the other collagens, types I, IH, and IV, it is 
important in mediating a signal fiom collagen V. Also important to reiterate is that 
patients who lack GPIV have no clinical bleeding signs (Saelman, 1994). Figures 11 
and 12 are examples of the results obtained from the two groups for CD36. The mean 
for the peak channels o f the nonpregnant and pregnant samples was 92.45 and 84.0, 
respectively, while the average of the mean channels was 110.77 and 145.22, 
respectively. Neither of the two t-tests showed significance at the 1% level. Table 5 
sums up the statistics for the two groups. Both t-values are within the +/- 2.750 range 
and therefore no statistical difference existed between the two groups for CD36.
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Figure 11. Non-pregnant CD36 flow cytometric results
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Figure 12. Pregnant CD36 flow cytometric results
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Table 5. CD36 Binding Results in nonpregnant and pregnant samples
Nonpregnant
(n=2 2 )
Pregnant
(n»18)
t-value *S/NS
Peak Channel 
CD36
92.45+/. 98.4 84.00+/- 53.7 0.328 NS
Mean Channel 
CD36
110.77+/-25.1 145.22+/-542 -2.65 NS
♦ Two-sided 99% confidence interval 
CD41
CD41 is an antibody, which binds to the cell surface glycoprotein GPIIb. In 
this study CD41 was examined in three different t-tests. The first one comprised of 
FITC bound Ab to just CD41. The next two were double labeled using CD41 as a 
platelet marker while assessing for activation using activation specific antibodies. 
One included FITC Abs to CD41 with a PE Ab to CD62 (see figures 21 and 22) and 
the third test used FITC Abs to PAC-1 (see figures 23 and 24) while the CD41 Ab 
was coupled to PE. Figures 13 and 14 show the results of the first t-test while table 6  
summarizes all of the results for CD41. The mean o f the peak chaimels for CD4I for 
the two groups was 781.14,791.73 (coupled with CD62), and 1574.55 (coupled with 
PAC-1) for the nonpregnant group and 934.28,966.72, and 2395.28, respectively, for 
the pregnant group. The average of the mean channel for nonpregnant group was 
787.09, 788.00 (coupled with CD62), and 1781.14 (coupled with PAC-1) while the 
pregnant group had values o f994.33,1081.72, and 2700.33, respectively. Four of 
these showed statistically significant differences between the two groups. The CD41 
FITC mean chaimel had a t-value of -3.37. The CD41 FITC mean chaimel with 
CD62 double labeling had a t-value of -4.77, vdule both peak and mean channels for
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Figure 13. Non-pregnant CD4I FITC flow cytometric results
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Figure 14. Pregnant CD41 FITC flow cytometric results
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CD41 PE (coupled with PAC-1) were statistically difiTerent, t-values o f -5.38 and-8.52
respectively.
Table 6 . CD41 Binding Results in nonpregnant and pregnant samples
Nonpregnant
(n=22)
Pregnant
(n=18)
t-valne *S/NS
Peak Channel CD41 
FTTC
781.14+/- 134.4 934.28+/-337.7 -1.95 NS
Mean Channel CD41 
FTTC
787.09+/-64.4 994.33+/-279.8 -3.37 S
Peak Channel CD41 
FITCW/CD62
791.73+/- 129.7 966.72+/-270.6 -2 . 6 8 NS
Mean Channel CD41 
FITCW/CD62
788.00+/- 55.6 1081.72+/-282.7 -4.77 S
Peak Channel CD41 
PE w/PAC-1
1574.55+/-320.4 2395.28+/- 622.0 -5.38 s
Mean Channel CD41 
PE w/PAC-1
1781.14+/-271.5 2700.33+/-408.0 
* Two-sided 99% confidence interval
-8.52 s
CD42a
CD42a is an antibody to GPIX. This is a member of the larger receptor 
known as GPIb, which initiates primary platelet adhesion to vWF during hemostasis. 
The peak channel for CD42a had a mean o f288.59 for nonpregnant group and 253.11 
for the pregnant group, while the average of the mean channels was 324.45 and 
274.50 respectively. Figures 15 and 16 are examples of the dot plot and histograms 
obtained for CD42a while table 7 summarizes the results and statistics for CD42a. 
Neither the peak nor mean channels showed any statistical difference.
Table 7. CD42a Binding Results in nonpregnant and pregnant samples
Nonpregnant
(n=22)
Pregnant
(n=18)
t-value *S/NS
Peak Channel 
CD42a
288.59+/- 57.6 253.11+/-88.5 1.52 NS
Mean Channel 
CD42a
324.45+/-39.1 274.50+/-77.3 2.65 NS
Two-sided 99% confidence interval
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Figure 15. Non-pregnant CD42a flow cytometric results
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Figure 16. Pregnant CD42a flow cytometric results
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CD42b
CD42b is also known as GPIba, which is another member, besides CD42a, of 
the GPIb comploc, which again is responsible for prim ary adhesion o f the platelet to 
vWF. The peak channel and mean channel was 265.50 and 348.50 respectively for 
the nonpregnant groiq) while the pregnant group had values o f260.83 and 305.94, 
respectively. Figures 17 and 18 show the results o f CD42b and table 8  sums up the 
statistics and averse values for peak and mean channels of the two groups o f 
subjects. Like CD42a, CD42b did not show any statistically significant differences.
Table 8 . CD42b Binding Results in nonpregnant and pregnant samples
Nonpregnant
(n=2 2 )
Pregnant
(n=18)
t-value *S/NS
Peak Channel 
CD42b
265.50+/- 78.4 260.83+/- 157.8 1.23 NS
Mean Channel 
CD42b
348.50+/- 112.5 305.94+/- 154.9 1 . 0 1 NS
* Two-sided 99% confidence interval 
CD61
CD61 is an antibody to GPllIa, which is a member of the platelet receptor 
more commonly known as GPllb/ lHa. CD41 is the Ab to GPllb while the 
noncovalently linked second subunit GPlllahas CD61 as the Ab to it. 796.23 and 
797.77 are the peak and mean channel averages for the nonpregnant group, while 
811.44 and 861.06 are the means ofthe pregnant group. Figures 19 and 20 are 
examples of the results obtained for CD61. Table 9 shows the averages of the peak 
and mean channels for CD61 along with the t-values calculated. No statistically 
significant differences are noted.
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Figure 17. Non-pregnant CD42b flow cytometric results
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Figure 18. Pregnant CD42b flow cytometric results
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Figure 19. Non-pregnant CD6I flow cytometric results
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Figure 20. Pregnant CD61 flow cytometric results
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Table 9. CD61 Binding Results in nonprcgnant and pregnant samples
Nonpregnant
(n=2 2 )
Pregnant
(n=18)
t-value *S/NS
Peak Channel 
CD61
796.23+/- 150.0 811.44+/-382.2 -0.17 NS
Mean Channel 
CD61
797.77+/- 80.6 861.06+/- 380.9 -0.76 NS
* Two-sided 99% confidence interval 
CD62
CD62 is the platelet adhesion molecule known as GMP-140. It is normally 
sequestered on the inner surface o f the a-granules and only during degranulation 
would it be e^qwsed on the platelets outer surface and accessible to the Ab. It is 
therefore an indicator o f platelet activation. Figures 21 and 22 are examples of the 
results obtained fiom CD62 while table 10 summarizes the statistics for CD62. The 
average of the peak channels for the nonpregnant and pregnant groups were 16.50 and 
21.12, respectively while the mean channel had averages o f42.70 and 75.53, 
respectively. Besides just recording peak and mean channels, wdnch did not show 
any statistical difference (t-values o f -1.09 and -1.43, respectively), the percent of 
platelets with the CD62 marker was also recorded. The percent of platelets with 
CD62 binding was 0.71% for nonpregnant females while the pregnant females had 
20.19% binding. This was indicative that the percent of platelets with a -  granule 
release was different between the two groups (t-value of -5.24).
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Figure 21. Non-pregnant CD62 flow cytometric results
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Figure 22. Pregnant CD62 flow cytometric results
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Table 10. CD62 Binding Results in noi^iegnant and pregnant samples
Nonpregnant
(n=2 2 )
Pregnant
(n=18)
t-valne *S/NS
% with CD62 
m arker
0.71+/-0.7 20.19+/- 17.5 -524 S
Peak Channel 
CD62
16.50+/- 15.4 21.12+/-9.7 -1.09 NS
Mean Channel 
CD62
42.70+/-83.6 75.53+/-54.4 -1.43 NS
* Two-sided 99% confidence interval 
PAC-I
PAC-1 is another platelet activation marker, ^Aiiich binds to activated GPIIb/ 
ma. Only after a process called inside-out signaling (see pages 22-23) does this 
marker present itself. Again, like CD62 it is important to consider the percentage of 
platelets with this marker besides the peak and mean channels of the ones that have i t  
The peak channel for the two groups was 673.41 and 1386.10 for the nonpregnant and 
pregnant groups while the mean channel had averages o f787.82 and 1890.50 
respectively. The percent o f platelets with PAC-1 binding was 0.48 and 0.33 for the 
nonpregnant and pregnant samples. Figures 23 and 24 are examples o f the results o f 
the pregnant and nonpregnant samples while table 11 summarizes the statistics. Here 
it is important to note the besides no statistical differences seen in peak and mean 
channels (t-values o f-1.13 and -1.78, respectively), no statistical difference in the 
percent of platelets showing this activation marker was seen (t-value of 0 .8 6 ).
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Figure 23. Non-pregnant PAC-1 flow cytometric results
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Figure 24. Pregnant PAC-1 flow cytometric results
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Table 11. PAC-1 Binding Results in noi^regnant and pregnant samples
Nonpregnant
(n=2 2 )
Pregnant
(n-18)
t-valne *S/NS
% with PAC-1 
marker
0.48+/-0.58 0.33+/-0.47 0 . 8 6 NS
Peak Channel 
PAC-1
673.41+/- 1696.9 1386.10+/-2302.6 -1.13 NS
Mean Channel 
PAC-1
787.82+/- 1665.6 1890.50+/-2251.0 -1.78 NS
Two-sided 99% confidence interval
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Chapter 5 
Discussion
Overview
During nonnal pregnancy changes do occur on the platelet surâce. In the 
results section it was shown that certain receptors do change in numbers. It is 
interesting that in all receptors that did statistically change in peak or mean channel 
values between nonpregnant and pregnant females, the platelet receptors were 
upregulated during pregnancy. This could potentially lead to abnormal platelet 
activation leading to aggregation. This supports the quote hom the pre-eclampsia 
introduction, “during normal pregnancy there are various effects on the coagulation 
system that have been compared to a chronic state o f compensated DIC” (Perry, 
1992). More importantly, both hypotheses, stated in chapter 1, would be supported 
by the results presented in chapter 4:
1) During normal pregnancy, there are increases in platelet proteins, which are
essential for platelet function.
->While not all o f the platelet proteins did increase during pregnancy, two of 
them involved in platelet aggregation did, GPIIb and CD29, a collagen receptor.
2) During pregnancy there is an increase in circulating activated platelets.
->This hypothesis vdiile it seems was proven needs to be looked at more
closely. Since one activation marker did indicate an increase in circulating activated 
platelets the other, more accurate, marker did not indicate this. In the discussion on 
activation markers this topic will further be explored.
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Demographics
The ages were similar between the two groups, as were the platelet counts and 
MPV. This indicates that the groups were comparable. There was a difference on the 
issue o f smoking. It is backward logic that a greater number o f females would smoke 
during pregnancy than nonpregnancy (3 vs 0). This is where a  limitation in the study 
arises. While the two groups o f females are comparable (see above), the populations 
from which they were obtained were different The pregnant females were obtained 
from a general OB/GYN practice in Grand Rapids while the nonpregnant females 
were all students in a graduate class taken by health professionals. This set o f health 
professional students would be more informed and concerned with the risks of 
smoking than the general population. Since smoking affects the cardiovascular 
system it could have slightly skewed the data showing a larger increase in platelet 
changes than was actually there.
The difference in medications is also worth mentioning. Eleven o f the 
nonpregnant females (50%) were on contraceptives while the only medications the 
pregnant females were on were prenatal vitamins. Obviously, only the nonpregnant 
females would be on contraceptives. It is not known, though, if  contraceptives affect 
platelets and this may affect the results.
A third point to mention in the demographics data is prior pregnancies. These 
were not statistically different and this is important to note because preeclampsia is 
seen in a greater m ajori^ during the first pregnancies. Since both groins had similar
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numbers and the pregnancy group had an average o f 1 . 8  prior pregnancies this can be 
seen as equal in both groups and therefore not be a significant difference.
Platelet receptors
This study looked at six different platelet receptors. Two of them showed 
significant increases during pregnancy, CD29 and CD41. The purpose of this study 
was to see what changes occur during pregnancy and that is why both peak and mean 
channels were examined.
Both peak and mean channels were used in the analysis to identify differences 
in binding of the antibody to the platelet surfiice. Peak channel is the channel 
“median”, which shows maximal binding of the specific Ab, A i^iile mean channel is 
the average channel of fluorescence taking into account all channels showing 
fluorescence in the positive region of the histogram. Both were used in identifying 
the potential differences in the two groups.
CD29 showed a significant (t-value of —5.34) increase in peak channel in the 
pregnant samples while the mean channel was within the normal range (t-value o f— 
2.24). This translates into the “median” value of CD29, a general attachment protein 
to the ECM, increases during normal pregnancy. ^  there is an increase in a receptor 
that is responsible for general attachment this would make the platelet more “sticlfy’ 
leading to the platelet to be activated more easily which supports both hypotheses.
The other platelet receptor that showed a significant increase between the 
nonpregnant and pregnant groups was CD41 or the GP Ilb receptor. This is part of 
the receptor complex of GP lib/ lUa. CD41 binds to both the activated and 
imactivated GPIIb/ Ilia complex. An increase in the binding was observed in
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pregnancy. This increase may represent anupregulation in. the proteins. Because 
GPIIb is involved in platelet aggregation through fibrinogen ^ b )  binding, an 
upregulation may represent an increase in aggregation abili^ once activation has 
occurred. An increase in this receptor (supporting hypothesis #1) could lead to an 
increase in circulating activated platelets (hypodiesis #2). The mean channels of all 
CD41s showed significant increases in the pregnancy group (-3.37, -4.77, & -8.52) 
while only the CD41 PE showed a significant increase in peak channel (-5.38). 
Overall, this supports the fact that CD41 very much increases during normal 
pregnancy.
An important corollary to this is that GP lUa (CD61), the partner to GP 11b 
did not show any significant increases during pregnancy (t-values of -0.17 & -0.76). 
While these two are generally considered as one receptor, they are separate proteins 
and in the normal platelet they are noncovalentiy held together via Ca^\ An increase 
in GP nb with no corresponding increase in GP lUa would yield extra GP Hb not 
being able to be coupled to GP lUa. What effect, if  any, this causes would need to be 
further investigated.
The other main receptor complex examined in this study was the complex of 
GP lb. This study looked at two subunits o f the larger complex CD 42a (GP IX) and 
CD 42b (GP Iba). There were slight decreases in both of these during pregnancy, but 
neither was statistically significant so no change between the two groups can be 
assumed. Since the GP Ib complex is responsible for initial platelet adhesion via 
vWF, no change in primary platelet adhesion via GPIb/ GPIX can be assumed. vWF 
though, does increase during normal pregnancy, so an idea could be put forth that
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platelet adhesion could still increase by the greater amount o f vWF saturating the GP 
Ib complex more readily leading to an increase in primary platelet adhesion.
The last platelet receptor examined in this study was CD 36, the platelet 
receptor for collagen V. No statistically significant changes were seen with this 
receptor (t-values o f0.328 & -2.65). Collagen V is not a very abundant form of 
collagen and therefore no increase in this receptor does not really say anything about 
platelet function or stqiport or disprove either o f the hypotheses.
Platelet Activation Markers 
Two platelet activation markers were examined in this study, GMP-140 (CD 
62) and PAC-1 (activated GP lib/ ma). While neither one o f these showed 
significant differences between the two groups with regard to peak or mean channels, 
there was a difference when it came to percentage expressing these markers.
The nonpregnant group expressed the GMP-140 receptor on 0.7% of the 
platelets while over 2 0 % of the pregnant sample expressed this activation marker. 
This is in contrast to the activated GP lib/ m a marker, PAC-1, vdiich showed no 
significant difference between the two groups (t-value o f0.856). This is where 
another limitation arises in the study. While all o f the nonpregnant samples were 
fixed within one minute o f collection, not all the pregnant samples could be fixed so 
quickly. This extra time, though not much more, could lead to platelet degranulation 
and therefore expression o f GMP-140, CD62. On the other hand PAC-1 expression, 
which is activated GP fib/ m a requires a stronger agonist for its expression to be seen 
on the platelet when compared to GMP-140. Pages 22-23 in chapter two describe this 
process of inside out signaling that occurs to yield the expression of this activation
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marker. Thus, wiiile it seems that the pregnancy sample did have an increased 
number o f activated platelets fiirther studies need to be done to make a concrete 
conclusion.
Limitations
Certain limitations, besides the ones already mentioned above, were present in 
this study and could not be controlled. EDTA was used as the anticoagulant in the 
blood samples. It is a Ca^  ^chelator and therefore EDTA will bind the Ca2+. GPUb/ 
n ia  is noncovalentiy held together via Ca?^ and EDTA could therefore disrupt this 
relationship if  it is ^ ing  up the Ca^\ This would prevent proper PAC-1 expression 
firom occurring and would therefore lead to the results seen with PAC-1 expression. 
Studies using different anticoagulants (non-Ca^^ chelators) would need to be done to 
overcome this limitation.
Another limitation involves the populations from which each sample group 
was obtained. Again, as was mentioned above, one group was obtained from the 
general population while the other was from a graduate class of health professionals. 
There are confounding factors that can not be accounted for and therefore this needs 
to be mentioned as a limitation.
A third limitation was the time between Wien the samples were drawn and 
fixed. All nonpregnant samples were fixed immediately while some of the pregnant 
samples had a short amount of time go by before fixing was done. How much, if any, 
this affected platelet activation is not known and therefore needs to be mentioned here 
as a limitation.
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Spectrum Health
May 10, 1999 Dmmnm Campus
lOO MICHIGAN STREET NE GRAND RAPIDS MI 4 9 5 0 3 -2 5 6 0  
6163911774  FAX 3 9 1 2745 wwwjpectrum-health.org
Theresa Bacon-Baugley, PhD.,
233 Padnos
Hall o f Science, School o f Heahh Science 
Allendale, MI 49401-9403
Dear Dr. Bacon-Bagufey:
A t the May 4,1999, meeting o f the Spectrum Health Research & Human Rights Committee your 
protocol entitled "Clinical Divestigatkm on the Assessment o f Platefet Structure and Function m 
Normal and Preeclamptic Patients" (MM-10), and the consent foim , were reviewed and given 
annual reapprovaL
The Research and Human R ifats Committee and the FD.A. requires you submit in writing, a 
progress report to the Committee ly  April 1,2000, and you will need reapproval should your 
study be ongoing at that time. Failure to do so could result in suspension o f your study. Please 
also be advised no additional personnel may be added to this study, nor may they have any 
access to study information unless the committee has been so advised and an Assurance Form 
has been signed.
Please be advised that any une;q>ected serious adverse reactions must be promptly reported to 
the Research and Human Rights Committee within (S) five days and all changes made to the 
study after initiation require prior approval o f  the Human Rights Committee before changes are 
implemented.
I f  you have any questions, please phone me or Linda Pool at 391-1291M299.
Sincerely,
Jeffrey S. Jones, M.D.
Chairman, Spectrum Health Research &  Human Rights
JSJ^fii
c: Russell Jelsema, M.D.
FUe
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Informed Consent Form
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INFORMED CONSENT INFORMATION FOR THE 
CLINICAL INVESTIGATION ON THE ASSESSMENT OF 
PLATELET STRUCTURE AND FUNCTION 
IN NORMAL AND PREECLAMPTIC PATIENTS
INTRODUCTION
Platelets play a significant role in the prevention of bleeding. During blood vessel 
injury, platelets adhere to die site o f injury and form a platelet plug. The platelet 
plug effectively forms a seal at the site of injury. A deficiency in die number o f 
platelets or in the ability^  o f platelets to form a platelet ping results m excessive 
bleeding even in the event o f minor trauma. In a pregnancy complicated by 
preeclampsia there is a h i^  incidence of thrombocytopenia, low platelet count It 
has riot been determined the exact nature of the thrombocytopenia. Therefore, you 
partic%)ation in the study may he^ in detemmmtgthe cause o f the thrombocytopenia 
as well as aid in the prediction o f impending complications.
PURPOSE AND RESULTS OF THE RESEARCH
The purpose of this study is to analyze both the function and structure of blood 
platelets from normal and preeclamptic pregnant females. The results of the 
platelets studies will be used to identify changes m preeclanqrtic females uiuch 
could be used to predict subsequent complications and to aid in the future treatment 
in preeclaixptic females.
PROCEDURES
There will be approximately 50 participants in the study.
As a participant, you will have 6 ml of blood removed via venqpuncture.
POTENTIAL BENEFITS
The benefits of this study may include a contribution to the overall understanding on 
platelet structure and function in preeclamptic females which may result in changes 
in the treatment of platelet disorders during preeclampsia.
POTENTIAL RISKS
The associated risks of venqpuncture include a bruise at the she of puncture, 
inflammation of the vein and/or infectioiL
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STUDY PARTICIPATION AND MEDICAL RECORDS ACCESS 
You have the right to refuse paitic^tian in the stucfy if  so desired at any time 
during the procedure whbout penalty^  or jeopardy o f the quality or quantity o f 
treatment you are now receiving or may receive in the future at Butterwoith 
Hospital hi case ofa  problem or emeigency, you can reach Dr. R. Jelesma at (616) 
732-3681 or call Dr. Theresa Bacon-Baguley at (616) 895-3289.
The doctor and/or his representative at Butterwofth Hospital may inspect your 
medical records for mformation pinposes Wiere expropriate and necessary. You 
are assured that your ccmfidentiality will be preserved and tiiat your name not be 
revealed in any publications or presentation resulting fiom this study without your
eiqiressed consent
Questions regarding your rights as a paiticqiant can be answered by calling the 
Human Right's Committee representative, Linda Pool, at the following number
(616)774-1291/1299.
FINANCIAL RESPONSIBILITY/STUDY RELATED PERSONAL INJURY
You will receive no payment for your partic^tion in the study.
Costs associated with any injury will not be covered by the investigator or by 
Butterworth Hospital Your signature on the consent form indicated that you have 
volunteered to partic^te in the study and have read the information provided.
CONCLUSIONS
I have read this informed Consent and agree to participate in this research study. I 
will be provided with a copy o f  this consent fom L
Signature of Patient Date
Signature offovestigator Date
Signature of Wimess Date
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SUBIECTMUMBEH___
DATE BLOOD DRAWW 
DATE BLOOD ANALYZED
FLOW CYTOMETRIC ANALYSIS OF PLATELET 
STRUCTURE IN NORMAL AND HYPERTENSIVE 
PREGNANT FEMALES 
SUBJECT CHARACTERISTICS
Patient ID Number 
Patient Age:
Prior pregnancies: 
Number o f live bntbs: 
EDC(PregQBnt subjects): 
Subject Group
Non-Pregnant 
Normal Pregnant 
PIE
Preeclampsia
Eclampsia
Other
Medical History Nd Yes Explain
Allergies ___ ___ ______
Bleeding disorders _
Diabetes _
Cardiovascular Disease _
Smoker____________________
Other Significant Medical History
Medications(Over Ae counter & Prescrqitive):
Pregnancy Outcome
  Nonnal Vaginal Delivery
  C-Scction
  Delivery complications (explain)
Post-partum complications:
S6
